The rise of Ozempic and Wegovy, two medications containing semaglutide, has sparked a surge in poison control calls, raising concerns about misuse and mishandling. This trend is particularly intriguing given the drugs' approval for chronic weight management in 2021. Jordan Miller, an undergraduate student at UT San Antonio, embarked on a research project to investigate the connection between the FDA's expanded approval and the increase in poison control cases. Collaborating with David Han, Robert S. Miller, and Shawn M. Varney, Miller analyzed national poison control data, uncovering a dramatic shift in call volumes and types post-approval. The findings revealed that the FDA's approval marked a turning point, with a significant rise in poison control calls, reflecting the drug's expanded use beyond diabetes treatment to weight management. This expansion led to a surge in calls, with semaglutide cases dominating the statistics. The research highlights the importance of data science in identifying public health trends and the need for better patient education to prevent preventable dosing mistakes. The study's findings were published in prestigious journals, emphasizing the impact of semaglutide on public health and the potential risks associated with its misuse. This article delves into the implications of the research, exploring the relationship between medication approval, public health, and the role of education in preventing adverse events.
